Clinical Trials Logo

Sclerosis clinical trials

View clinical trials related to Sclerosis.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05866926 Terminated - Clinical trials for Amyotrophic Lateral Sclerosis

Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis

ADOREXT
Start date: March 6, 2023
Phase: Phase 3
Study type: Interventional

A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis

NCT ID: NCT05442775 Terminated - Clinical trials for Amyotrophic Lateral Sclerosis

A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

COURAGE OLE
Start date: July 25, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the long-term safety and tolerability of reldesemtiv in patients with ALS who have successfully completed dosing in the Phase 3 clinical trial, CY 5031 (also known as COURAGE-ALS)

NCT ID: NCT05427045 Terminated - Multiple Sclerosis Clinical Trials

A Pilot Project for Multifidus Muscle Evaluation in Patients With Multiple Sclerosis

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

This research study plans to evaluate if multifidus muscle dysfunction is associated with back pain in patients with Multiple Sclerosis (MS).

NCT ID: NCT05081271 Terminated - Multiple Sclerosis Clinical Trials

COVID-19 Booster Vaccination in Persons With Multiple Sclerosis

Start date: October 15, 2021
Phase: Early Phase 1
Study type: Interventional

The success of the U.S. vaccination program against SARS-Cov-2 is shown by a dramatic drop in infection rates, hospitalizations and deaths.However, it appears that many persons who take medications that chronically suppress the immune system do not produce neutralizing antibodies to COVID-19 proteins in response to vaccination. This group includes a significant number of persons with multiple sclerosis (PWMS), many of whom are on therapies that chronically suppress their immune function. It is unclear what advice clinicians should provide regarding COVID-19 precautions to patients who fail to develop detectable COVID-19 spike protein antibodies using standard commercially-available tests after a standard series of vaccination, or whether they should test for antibody responses to COVID-19 vaccines in the absence of guidelines. A key research question is whether, in the absence of stopping or reducing potentially immune-altering therapies, there is a way to increase the likelihood of a neutralizing antibody response to COVID-19 vaccination in PWMS who are taking immune suppressive medications.

NCT ID: NCT05053035 Terminated - Clinical trials for Amyotrophic Lateral Sclerosis

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

Start date: September 2, 2021
Phase: Phase 2
Study type: Interventional

A phase 2 double-blind, placebo-controlled study of AL001 in participants with C9orf72-associated ALS.

NCT ID: NCT05049161 Terminated - Multiple Sclerosis Clinical Trials

A Long-term Extension of Study GNC-401

Start date: August 27, 2021
Phase: Phase 2
Study type: Interventional

This Phase II study is a monocenter, long-term extension study of study GNC-401 and will start after individual completion of Week 48 of the GNC-401 study. At entry, all patients will receive active treatment with temelimab. The patients of the placebo group in study GNC-401 will be re-randomized to temelimab 18 mg/kg, 36 mg/kg or 54 mg/kg (1:1:1), while the patients who received temelimab in study GNC-401 will continue with the same dose in study GNC-402. Following final analysis of the results of the GNC-401 study, the Sponsor may switch all patients to an optimal dose of temelimab based on safety and efficacy demonstrated in the GNC-401 study.

NCT ID: NCT04990219 Terminated - Multiple Sclerosis Clinical Trials

A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis

Start date: September 27, 2021
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to investigate Lu AG06466 as a treatment for spasticity in participants with multiple sclerosis (MS).

NCT ID: NCT04984278 Terminated - Clinical trials for Spasticity With Multiple Sclerosis

Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

RELEASE MSS5
Start date: August 16, 2021
Phase: Phase 3
Study type: Interventional

This study will be conducted to evaluate the effect of multiple doses of nabiximols compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Lower Limb Muscle Tone-6 [LLMT-6]) in participants with multiple sclerosis (MS). LLMT-6 is defined as the average of the 6 individual Modified Ashworth Scale (MAS)-transformed scores of knee flexors, knee extensors, and plantar flexors on both sides of the body.

NCT ID: NCT04971005 Terminated - Clinical trials for Relapsing-Remitting Multiple Sclerosis

Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial

COAST
Start date: August 27, 2021
Phase: Phase 2
Study type: Interventional

A multicentre controlled phase II trial to compare the efficacy and safety of ocrelizumab or alemtuzumab and autologous Hematopoietic Stem Cell Transplantation (aHSCT). Active relapsing-remitting MS-Patients will be included and randomised to ocrelizumab or alemtuzumab versus aHSCT. Primary endpoint will be the time to treatment failure as assessed by failure of NEDA (no evidence of disease activity) as represented by: no expanded disability status scale (EDSS) progression, no relapse, no new T2 lesion and no Gd-enhancing lesion. This trial offers the opportunity to gain further information about efficacy and safety of all treatments and will give new insights into the immunology of highly active RRMS.

NCT ID: NCT04948554 Terminated - Clinical trials for Systemic Sclerosis With and Without Interstitial Lung Disease

A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)

Start date: March 10, 2023
Phase: Phase 1
Study type: Interventional

The purpose of the MK-2225-002 (A1334-02) study is to evaluate the safety and tolerability of MK-2225 (ACE-1334) plus standard of care (SOC) in participants with Systemic Sclerosis (SSc) following multiple doses.